Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Jonsson Comprehensive Cancer Center |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00006341 |
RATIONALE: The use of dentures and dental implants may help maintain chewing and speaking ability following surgery to remove tumors in the mouth.
PURPOSE: Phase II trial to study the effectiveness of dentures and dental implants in maintaining the ability to chew and speak in patients undergoing surgery for mouth cancer.
Condition | Intervention | Phase |
---|---|---|
Cancer-Related Problem/Condition Head and Neck Cancer |
Procedure: conventional surgery Procedure: management of therapy complications Procedure: quality-of-life assessment Radiation: radiation therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Supportive Care |
Official Title: | Efficacy of Implant-Supported Maxillofacial Prostheses |
Estimated Enrollment: | 62 |
Study Start Date: | June 1997 |
OBJECTIVES:
OUTLINE: Patients complete a series of objective and subjective functional tests, questionnaires, and baseline examinations. Within 1-5 days, patients undergo the composite resection, including reconstructive surgery for the mandibulectomy group. Patients in the maxillectomy group receive an immediate maxillary surgical obturator. Approximately 6 weeks after ablative surgery, some patients receive radiotherapy for 5-7 weeks.
Patients receive 2-4 implants at 12-16 weeks after completion of radiotherapy or 8-16 weeks after ablative surgery. Patients then receive conventional dentures at 4-22 weeks after implant surgery. Implants are exposed during 27-48 weeks after placement and abutments connected for fabricating dental prostheses. Approximately 8 weeks are needed to fabricate the implant supported prosthesis.
Patients complete quality of life and other questionnaires prior to and at 8-21 weeks after surgery, 16 weeks after conventional denture insertion, and then 16 weeks after implant supported prosthesis insertion.
Patients are followed every 6 months for at least 3 years.
PROJECTED ACCRUAL: A total of 62 patients (22 requiring maxillectomy and 40 requiring mandibulectomy) will be accrued for this study within 42 months.
Ages Eligible for Study: | 35 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of early oral cancer lesions requiring one of the following:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
United States, California | |
Jonsson Comprehensive Cancer Center, UCLA | |
Los Angeles, California, United States, 90095-1781 |
Study Chair: | Neal R. Garrett, PhD | Jonsson Comprehensive Cancer Center |
Study ID Numbers: | CDR0000066588, UCLA-HSPC-940205413, UCLA-DEN-1R01DE11255, UCLA-HSPC-940205411, NCI-V00-1606 |
Study First Received: | October 4, 2000 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00006341 History of Changes |
Health Authority: | United States: Federal Government |
stage I lip and oral cavity cancer stage II lip and oral cavity cancer stage III lip and oral cavity cancer oral complications quality of life |
Lip and Oral Cavity Cancer Head and Neck Neoplasms Quality of Life Mouth Neoplasms Oral Cancer |
Neoplasms Neoplasms by Site Head and Neck Neoplasms |